Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > 3rd quarter

<< Previous

Bullboard Posts

Next >>

Post by spesestsemperon Oct 28, 2024 11:16am

212 Views

Post# 36285029

3rd quarter

My account shows third quarter results on November 1st . Its strange in that they usually have a news release about a week in advance of the conference call . Can anyone confirm the november 1st date to be correct . Side note - for once I would like the shorts to be wrong .

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant